Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 22 | 2024 | 2303 | 1.290 |
Why?
|
| Medication Adherence | 3 | 2019 | 179 | 0.610 |
Why?
|
| Anti-HIV Agents | 5 | 2024 | 420 | 0.530 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2024 | 404 | 0.490 |
Why?
|
| Ambulatory Care Facilities | 2 | 2017 | 61 | 0.440 |
Why?
|
| Case Management | 1 | 2011 | 20 | 0.400 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2017 | 57 | 0.380 |
Why?
|
| Anti-Retroviral Agents | 2 | 2019 | 147 | 0.370 |
Why?
|
| Homosexuality, Male | 5 | 2019 | 458 | 0.360 |
Why?
|
| Sexual Partners | 8 | 2024 | 314 | 0.360 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2005 | 221 | 0.340 |
Why?
|
| Contact Tracing | 1 | 2007 | 19 | 0.310 |
Why?
|
| Hepatitis C | 2 | 2023 | 125 | 0.310 |
Why?
|
| Community-Institutional Relations | 2 | 2017 | 187 | 0.300 |
Why?
|
| Drug Resistance, Viral | 2 | 2005 | 63 | 0.300 |
Why?
|
| Los Angeles | 8 | 2022 | 380 | 0.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2024 | 864 | 0.260 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2020 | 164 | 0.260 |
Why?
|
| HIV-1 | 4 | 2017 | 706 | 0.250 |
Why?
|
| Didanosine | 1 | 2003 | 3 | 0.240 |
Why?
|
| Nevirapine | 1 | 2003 | 7 | 0.240 |
Why?
|
| Oxazines | 1 | 2003 | 26 | 0.230 |
Why?
|
| HIV | 1 | 2004 | 98 | 0.230 |
Why?
|
| Social Support | 4 | 2024 | 394 | 0.230 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 39 | 0.220 |
Why?
|
| Urban Population | 1 | 2024 | 333 | 0.200 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 94 | 0.200 |
Why?
|
| Humans | 24 | 2024 | 37093 | 0.190 |
Why?
|
| Sexual Behavior | 4 | 2024 | 609 | 0.190 |
Why?
|
| Adult | 15 | 2024 | 11712 | 0.180 |
Why?
|
| Male | 17 | 2020 | 20025 | 0.180 |
Why?
|
| Communication Barriers | 1 | 2020 | 56 | 0.180 |
Why?
|
| Mass Screening | 2 | 2014 | 462 | 0.170 |
Why?
|
| Condoms | 2 | 2019 | 135 | 0.170 |
Why?
|
| Risk-Taking | 7 | 2024 | 451 | 0.170 |
Why?
|
| Hepacivirus | 2 | 2023 | 62 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 191 | 0.160 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 10 | 0.150 |
Why?
|
| Patient Compliance | 3 | 2017 | 212 | 0.150 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2017 | 121 | 0.150 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 174 | 0.140 |
Why?
|
| United States | 7 | 2013 | 4223 | 0.140 |
Why?
|
| Female | 14 | 2024 | 20969 | 0.140 |
Why?
|
| Young Adult | 6 | 2024 | 4268 | 0.140 |
Why?
|
| Adolescent | 6 | 2017 | 5363 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2014 | 33 | 0.120 |
Why?
|
| Middle Aged | 9 | 2024 | 10129 | 0.100 |
Why?
|
| Viral Load | 3 | 2022 | 312 | 0.100 |
Why?
|
| Health Personnel | 1 | 2014 | 228 | 0.100 |
Why?
|
| Truth Disclosure | 1 | 2011 | 26 | 0.100 |
Why?
|
| Stereotyping | 1 | 2011 | 40 | 0.100 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 11 | 0.100 |
Why?
|
| Stress, Psychological | 3 | 2013 | 583 | 0.100 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 13 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 198 | 0.090 |
Why?
|
| Risk Factors | 4 | 2013 | 3562 | 0.090 |
Why?
|
| Antigen Presentation | 1 | 2010 | 54 | 0.090 |
Why?
|
| Sexuality | 1 | 2010 | 52 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2024 | 661 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2007 | 117 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2024 | 446 | 0.070 |
Why?
|
| Depression | 1 | 2013 | 712 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 128 | 0.070 |
Why?
|
| Chicago | 1 | 2005 | 30 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2005 | 42 | 0.060 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 125 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2007 | 753 | 0.060 |
Why?
|
| Professional-Patient Relations | 1 | 2004 | 48 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2010 | 1492 | 0.060 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 8 | 0.060 |
Why?
|
| Cyclopropanes | 1 | 2003 | 40 | 0.060 |
Why?
|
| Alkynes | 1 | 2003 | 50 | 0.060 |
Why?
|
| Benzoxazines | 1 | 2003 | 46 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 143 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 68 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 1378 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 189 | 0.060 |
Why?
|
| Logistic Models | 3 | 2013 | 923 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2024 | 127 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2023 | 157 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2003 | 301 | 0.050 |
Why?
|
| California | 2 | 2013 | 476 | 0.050 |
Why?
|
| AIDS Serodiagnosis | 1 | 2020 | 25 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2003 | 1369 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 2721 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1067 | 0.040 |
Why?
|
| Adenine | 1 | 2019 | 44 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 618 | 0.040 |
Why?
|
| Ritonavir | 1 | 2017 | 14 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2003 | 2026 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2017 | 61 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2019 | 161 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2017 | 56 | 0.040 |
Why?
|
| Patient Selection | 1 | 2017 | 164 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 885 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 170 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2014 | 86 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 233 | 0.030 |
Why?
|
| Morbidity | 1 | 2013 | 91 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2013 | 136 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 253 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 311 | 0.030 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 4 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 7 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 5 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 7 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 182 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 145 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 149 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 159 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 321 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 389 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 333 | 0.020 |
Why?
|
| Bisexuality | 1 | 2011 | 208 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 601 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 808 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 767 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 583 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 204 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 6741 | 0.010 |
Why?
|
| Heterosexuality | 1 | 2002 | 88 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1130 | 0.010 |
Why?
|